These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 5004903)

  • 21. [Pharmacokinetic study in the rat of a new hypoglycemic agent: glisolamide].
    Cerri L; Dalla Vedova R; Groppetti A
    G Clin Med; 1979 Nov; 60(11):903-10. PubMed ID: 546671
    [No Abstract]   [Full Text] [Related]  

  • 22. P-glycoprotein inhibition by glibenclamide and related compounds.
    Golstein PE; Boom A; van Geffel J; Jacobs P; Masereel B; Beauwens R
    Pflugers Arch; 1999 Apr; 437(5):652-60. PubMed ID: 10087141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Physiological and physicochemical bases of drug interactions in man.
    Dayton PG; Perel JM
    Ann N Y Acad Sci; 1971 Jul; 179():67-87. PubMed ID: 4105795
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral sulfonylureas for the treatment of type II diabetes: an update.
    Shank WA; Morrison AD
    South Med J; 1986 Mar; 79(3):337-43. PubMed ID: 3082015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Uptake of glibornuride by microdissected pancreatic islets.
    Täljedal IB
    Horm Res; 1974; 5(4):211-6. PubMed ID: 4210148
    [No Abstract]   [Full Text] [Related]  

  • 26. [Changes in blood glucose and insulin in 4 normal subjects after administration of a single dose of glipizide and glibenclamide].
    Rizzi G; Isaia GC
    Minerva Med; 1974 Jan; 65(1):58-9. PubMed ID: 4214132
    [No Abstract]   [Full Text] [Related]  

  • 27. Special pharmacology of the new sulfonylurea glimepiride.
    Geisen K
    Arzneimittelforschung; 1988 Aug; 38(8):1120-30. PubMed ID: 2904269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capillary electrophoretic detection of metabolites in the urine of patients receiving hypoglycemic drug therapy.
    Roche ME; Oda RP; Lawson GM; Landers JP
    Electrophoresis; 1997 Sep; 18(10):1865-74. PubMed ID: 9372282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Resorption, excretion and metabolism after intravenous and oral administration of HB 419-14C in man].
    Rupp W; Christ O; Heptner W
    Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1428-34. PubMed ID: 5394466
    [No Abstract]   [Full Text] [Related]  

  • 30. CYP105A1 mediated 3-hydroxylation of glimepiride and glibenclamide using a recombinant Bacillus megaterium whole-cell catalyst.
    Kleser M; Hannemann F; Hutter M; Zapp J; Bernhardt R
    J Biotechnol; 2012 Feb; 157(3):405-12. PubMed ID: 22202177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological characterization of the sulphonylurea receptor in rat isolated aorta.
    Löffler C; Quast U
    Br J Pharmacol; 1997 Feb; 120(3):476-80. PubMed ID: 9031752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug interactions with oral sulphonylurea hypoglycaemic drugs.
    Hansen JM; Christensen LK
    Drugs; 1977 Jan; 13(1):24-34. PubMed ID: 401727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Oral antidiabetics of the sulfonylurea group and their problems in therapy].
    Füsgen I; Summa JD
    Z Gerontol; 1980; 13(1):45-51. PubMed ID: 7456613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of sulfonylurea with the pancreatic B-cell.
    Gylfe E; Hellman B; Sehlin J; Täljedal B
    Experientia; 1984 Oct; 40(10):1126-34. PubMed ID: 6436052
    [No Abstract]   [Full Text] [Related]  

  • 36. Biotransformation of a new hypoglycemic agent, N-(p-toluenesulfonyl)-5-methyl-2-pyrazoline-1-carbonamide (SPC-703) in humans and rats.
    Jakubowski Z; Angielski S
    Pol J Pharmacol Pharm; 1980; 32(1):37-46. PubMed ID: 7454610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repaglinide and related hypoglycemic benzoic acid derivatives.
    Grell W; Hurnaus R; Griss G; Sauter R; Rupprecht E; Mark M; Luger P; Nar H; Wittneben H; Müller P
    J Med Chem; 1998 Dec; 41(26):5219-46. PubMed ID: 9857091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Studies on dose-response relationship of various sulfonylurea derivatives of the old and the new generation with further hints to extrapancreatic mechanisms of decreasing blood sugar].
    Haupt E; Köberich W; Cordes U; Beyer J; Schöffling K
    Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2203. PubMed ID: 4198968
    [No Abstract]   [Full Text] [Related]  

  • 39. [Kinetics of glibenclamide in the dog].
    Castoldi D; Chinea B; Tofanetti O
    Farmaco Prat; 1978 Jun; 33(6):271-5. PubMed ID: 105933
    [No Abstract]   [Full Text] [Related]  

  • 40. Antidiabetic sulfonylureas: localization of binding sites in the brain and effects on the hyperpolarization induced by anoxia in hippocampal slices.
    Mourre C; Ben Ari Y; Bernardi H; Fosset M; Lazdunski M
    Brain Res; 1989 May; 486(1):159-64. PubMed ID: 2497930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.